Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin (BCM95) in Relapsing Multiple Sclerosis
NCT01514370Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2012
- Primary completion
- Mar 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of curcumin in multiple sclerosis (MS), sponsored by Merck KGaA. Started Apr 2012; status: completed.
02
Drugs
curcumin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01514370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514370.